A Novel Tuberculosis DNA Vaccine in an HIV-1 p24 Protein Backbone Confers Protection against Mycobacterium tuberculosis and Simultaneously Elicits Robust Humoral and Cellular Responses to HIV-1

Clinical and Vaccine Immunology, 05/08/2012

The findings demonstrated that the pP24–Mtb tuberculosis vaccine confers effective protection against mycobacterial challenge with simultaneously elicited robust immune responses to HIV–1, which may provide clues for developing novel vaccines to prevent dual infections.

Print Article Summary Cat 2 CME Report